# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
BTIG analyst Thomas Shrader reiterates AC Immune (NASDAQ:ACIU) with a Buy and maintains $8 price target.
AC Immune (NASDAQ:ACIU) reported quarterly losses of $(0.21) per share which missed the analyst consensus estimate of $(0.17) b...
https://www.fda.gov/news-events/press-announcements/fda-clears-first-blood-test-used-diagnosing-alzheimers-disease#:~:text=The%...
HC Wainwright & Co. analyst Andrew Fein maintains AC Immune (NASDAQ:ACIU) with a Buy and lowers the price target from $1...
AC Immune (NASDAQ:ACIU) reported quarterly losses of $(0.21) per share which missed the analyst consensus estimate of $(0.20) b...